Recent clinical studies have demonstrated that MET amplification predicts that patients with lung cancer and activating EGFR mutations will fail to respond to erlotinib or gefitinib, and KRAS mutation predicts that patients with colon cancer will fail to respond to cetuximab [31], [32]. This evidence concerns the gene KRAS and colonic neoplasm.